News
Sarepta Shares Fall
Digest more
The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...
The European Medicines Agency’s drug advisory committee (CHMP) rejected Elevidys for children aged 3 to 7 years who are able ...
Roche is pausing shipments of Elevidys in some countries, following partner Sarepta Therapeutics’ move in the U.S., as safety ...
Sarepta downgraded as company suspends guidance after latest Elevidys death Jun. 16, 2025 11:31 AM ET Sarepta Therapeutics, Inc. (SRPT) Stock RHHBY , RHHBF By: Dulan Lokuwithana , SA News Editor ...
Sarepta halted Elevidys shipments for non-ambulatory patients and paused dosing in the ENVISION trial. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile. Sarepta and ...
ELEVIDYS Impact. Sarepta’s decision to stop shipping ELEVIDYS to treat non-ambulatory DMD patients could eliminate roughly 65% of the potential patient population. ... (anti-rejection graft ...
Nevertheless, on the same day, Sarepta assured investors that “the benefit-risk of ELEVIDYS remains positive.” Next, on June 15, 2025, Sarepta announced that a second patient treated with ...
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne Provided by Business Wire Jun 15, 2025, 5:00:00 AM.
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS, the only approved gene therapy for patients with Duchenne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback